Sam Brusco07.12.22
Philips has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its SmartSpeed artificial intelligence (AI)-powered MR acceleration software.
According to the company, adding advanced AI data collection algorithms to the existing SENSE MR acceleration engine delivers higher image resolution with three times faster scan times and “virtually no loss in image quality.”
“Philips’ AI-based SmartSpeed reconstruction is the new benchmark among acceleration techniques for us. It improves on the company’s existing Compressed SENSE in all aspects and allows a reduction in scan times with excellent image quality and diagnostic confidence,” Dr. Grischa Bratke, radiologist and expert in musculoskeletal imaging at the University Hospital of Cologne, Germany told the press.
The AI reconstruction algorithm is used at the MR signal’s front end to remove the noise and preserve details while enabling k-space data consistency check for trustworthy AI. It increases resolution up to 65% and achieves up to 3 times faster scanning times compared to conventional MR scans, according to Philips. It has support for 97% of current clinical protocols, including advanced contrasts and diffusion weighted imaging, as well as T1 or T2 mapping for brain, liver, heart, or musculoskeletal imaging.
“By taking the Quadruple Aim as a starting point to develop and deploy AI solutions, we have a tremendous opportunity to address the inefficiencies and growing demand that our customers and partners face every day,” said Kees Wesdorp, chief business leader of Precision Diagnosis at Philips. “Powered by AI, our leading technologies and smart connected imaging solutions help turn data into actionable insights to increase diagnostic confidence and help improve clinical outcomes for patients.’’
Last week, Philips also announced it was teaming up with data-driven diagnostic solutions company Biodesix to incorporate the results of Biodesix’s Nodify Lung blood-based lung nodule risk assessment testing into the Philips Lung Cancer Orchestrator lung cancer patient management system.
According to the company, adding advanced AI data collection algorithms to the existing SENSE MR acceleration engine delivers higher image resolution with three times faster scan times and “virtually no loss in image quality.”
“Philips’ AI-based SmartSpeed reconstruction is the new benchmark among acceleration techniques for us. It improves on the company’s existing Compressed SENSE in all aspects and allows a reduction in scan times with excellent image quality and diagnostic confidence,” Dr. Grischa Bratke, radiologist and expert in musculoskeletal imaging at the University Hospital of Cologne, Germany told the press.
The AI reconstruction algorithm is used at the MR signal’s front end to remove the noise and preserve details while enabling k-space data consistency check for trustworthy AI. It increases resolution up to 65% and achieves up to 3 times faster scanning times compared to conventional MR scans, according to Philips. It has support for 97% of current clinical protocols, including advanced contrasts and diffusion weighted imaging, as well as T1 or T2 mapping for brain, liver, heart, or musculoskeletal imaging.
“By taking the Quadruple Aim as a starting point to develop and deploy AI solutions, we have a tremendous opportunity to address the inefficiencies and growing demand that our customers and partners face every day,” said Kees Wesdorp, chief business leader of Precision Diagnosis at Philips. “Powered by AI, our leading technologies and smart connected imaging solutions help turn data into actionable insights to increase diagnostic confidence and help improve clinical outcomes for patients.’’
Last week, Philips also announced it was teaming up with data-driven diagnostic solutions company Biodesix to incorporate the results of Biodesix’s Nodify Lung blood-based lung nodule risk assessment testing into the Philips Lung Cancer Orchestrator lung cancer patient management system.